Alemtuzumab, a humanized monoclonal antibody, attenuates multiple sclerosis progression through CD52‐targeted depletion of T and B cells, thereby reducing central nervous system inflammation and demyelination (Table 1) [87]. Here, CD52 is linked to multiple sclerosis.